Drug combination for multiple myeloma with moderate liver problems
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a combination of three drugs (belantamab mafodotin, bortezomib, and dexamethasone) for people with multiple myeloma who also have moderate liver problems. The goal is to see if this combination is safe and works well for them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have a confirmed diagnosis of multiple myeloma.
- You must have had at least one prior treatment for multiple myeloma, and your disease must have progressed during or after that treatment.
- You need to have measurable signs of the disease, such as a certain level of M-protein in blood or urine, or increased plasma cells in the bone marrow.
- You must have either normal liver function or moderate liver impairment, as defined by specific blood tests.
- If you had a stem cell transplant in the past, it must have been more than 100 days ago, and you must be free of active infections.
- You must not have certain eye conditions, active bleeding, or serious unstable medical issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way of giving a combination of three drugs—belantamab mafodotin, bortezomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if a different dosing schedule is more effective and safer.
This trial tests a new combination of drugs for people with multiple myeloma whose cancer did not respond to or returned after one prior treatment with lenalidomide. The goal is to see if this combination is safe and effective.
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
This study tests a combination of four medicines (isatuximab, bortezomib, lenalidomide, dexamethasone) for people with newly diagnosed high-risk multiple myeloma who are not having a stem cell transplant. The goal is to see if this combination can better control the disease and improve outcomes.
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.